{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:19:17Z","timestamp":1783171157191,"version":"3.54.6"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82321003"],"award-info":[{"award-number":["82321003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["YTP-SYSUCC-PT22142001"],"award-info":[{"award-number":["YTP-SYSUCC-PT22142001"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["CIRP-SYSUCC-0004"],"award-info":[{"award-number":["CIRP-SYSUCC-0004"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM202211017"],"award-info":[{"award-number":["SZSM202211017"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024B1515020120"],"award-info":[{"award-number":["2024B1515020120"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.eclinm.2026.103980","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:19:57Z","timestamp":1778851197000},"page":"103980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-6235","authenticated-orcid":false,"given":"Miao-Zhen","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"M\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2026.103980_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103980_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2468-1253(19)30328-0","article-title":"The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017","volume":"5","author":"Stomach Cancer Collaborators","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103980_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and Trends--An update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103980_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/CEJ.0000000000000262","article-title":"Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China","volume":"26","author":"Zhao","year":"2017","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103980_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s44178-022-00004-x","article-title":"CACA guidelines for holistic integrative management of gastric cancer","volume":"1","year":"2022","journal-title":"Holist Integr Oncol"},{"key":"10.1016\/j.eclinm.2026.103980_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21037\/tgh.2020.02.08","article-title":"Molecular biology and immunology of gastric cancer peritoneal metastasis","volume":"5","author":"Yao","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"21","key":"10.1016\/j.eclinm.2026.103980_bib7","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.3390\/jcm10214882","article-title":"The burden of peritoneal metastases from gastric cancer: a systematic review on the incidence, risk factors and survival","volume":"10","author":"Rijken","year":"2021","journal-title":"J Clin Med"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2026.103980_bib8","doi-asserted-by":"crossref","first-page":"e16044","DOI":"10.1200\/JCO.2025.43.16_suppl.e16044","article-title":"Comparison of survival between liver-only metastasis and other metastatic sites in patients with de novo stage 4 gastric cancer: nationwide data from a single institute","volume":"43","author":"Shablak","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103980_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10294","key":"10.1016\/j.eclinm.2026.103980_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eclinm.2026.103980_bib11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103980_bib12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103980_bib13","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.eclinm.2026.103980_bib14","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.eclinm.2026.103980_bib15","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jama.2024.28463","article-title":"First-line sugemalimab plus chemotherapy for advanced gastric cancer: the GEMSTONE-303 randomized clinical trial","volume":"333","author":"Zhang","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103980_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.103980_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.02.003","article-title":"Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649","author":"Janjigian","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103980_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103980_bib19","doi-asserted-by":"crossref","first-page":"S893","DOI":"10.1016\/j.annonc.2024.08.1503","article-title":"1437P Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC\/GEJC): RATIONALE-305 study minimum 3-year survival follow-up","volume":"35","author":"Cruz-Correa","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103980_bib20","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.annonc.2024.05.312","article-title":"397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC\/GEJC): PD-L1 biomarker analysis from RATIONALE-305","volume":"35","author":"Moehler","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2026.103980_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103980_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:42:20Z","timestamp":1783168940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026002282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"alternative-id":["S2589537026002282"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103980","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103980"}}